Introduction
============

Inflammation is a characteristic feature of disease pathology and progression in several neuro-degenerative disorders and physical functioning \[[@R1]--[@R2]\]. Recently, nonsteroidal anti-inflammatory drugs (NSAIDs) are well established for the treatment of inflammatory disorders \[[@R3]--[@R5]\]. The anti-inflammatory effect of NSAIDs is mainly based on the inhibition of the cyclooxygenase (COX) enzymes. Later on, it was reported that the second isoform of cyclooxygenase (COX-2) has a better effect on the inflammation with fewer side-effects \[[@R6]--[@R9]\]. Despite their widespread use, none of the presently available agents is ideal; each has its own shortcomings \[[@R3]\]. Subsequently, to improve the efficacy/safety profile of new NSAIDs, the structural--activity relationship (SAR) has been extensively studied, taking into account up-to-date knowledge about the mechanism of inflammation that balanced the inhibition of COX-1, COX-2, and lipoxygenase (LOX) \[[@R10]--[@R12]\].

As a part of our continued interest in the development of convenient synthetic approaches to β-enamino- and α-aminophosphonates with anti-inflammatory properties \[[@R13]--[@R20]\], we recently successfully synthesized a series of mono- and bisphosphonate-based tetrazolo\[1,5-*a*\]quinolines with marked anti-inflammatory properties \[[@R21]--[@R22]\]. Following this, synthesis of the target compounds, substituted tetrazolo\[1,5-*b*\]pyridazinphosphor esters, is described herein. In this context, we applied different types of phosphonyl carbanion reagents to 3,6-diazidopyridazine (**1**) as an adopted substrate. The anti-inflammatory and the antinociceptive properties of the prepared compounds were screened and the structure--activity relationships were studied. The anti-inflammatory properties of many tetrazole \[[@R21]--[@R23]\] and pyridazine derivatives have also led to their clinical application as NSAIDs (e.g. Bucolome) \[[@R24]\]. Several phosphonate derivatives also exhibit marked potency as inhibitors of COX-1 and COX-2 and are therefore believed to be useful as anti-inflammatory drugs \[[@R25]--[@R26]\]. Thus, we considered that it is of interest to gather these three motifs in one molecule.

Results and Discussion
======================

It has been reported that 3,6-diazidopyridazine presents azido (**1a**) ![](Beilstein_J_Org_Chem-09-1730-i001.jpg) tetrazolo tautomerism (**1b**) whereby it is mainly in the tetrazole form **1b** \[[@R27]--[@R29]\]. Accordingly, and as indicated from the spectral data of our products, we considered that the substrate 3,6-diazidopyridazine (**1a**) is exclusively, throughout our investigation, reacted in the tetrazolo-form **1b** \[[@R28]--[@R29]\] ([Scheme 1](#C1){ref-type="fig"}). The required \[3,6-diazidopyridazine (**1a**) ![](Beilstein_J_Org_Chem-09-1730-i001.jpg) 6-azidotetrazolo\[1,5-*b*\]pyridazine (**1b**)\] was prepared by treating the readily available 3,6-dichloropyridazine with sodium azide \[[@R30]\]. The reactions studied and the products obtained are depicted in Schemes 1--7 (see below). Reaction of **1b** with 1.3 equivalents of methyl diethyl phosphonoacetate (**2a**) or the ethyl analogue **2b** in sodium ethanolate solution resulted in the same product assigned as diethyl 8-oxo-7,8-dihydroimidazo\[1,2-*f*\]tetrazolo\[1,5-*b*\]pyridazin-7-ylphosphonate (**4**, 78%) as indicated from the analytical and the spectroscopic data.

In the ^1^H NMR spectrum (CDCl~3~) of **4** (δ~P~ **=** 28.4 ppm) there is a doublet peak (^2^ *J* ~P--H~ = 22.3 Hz) at δ 5.36 ppm corresponding to H(4) of the imidazole ring while its C(4)--P appeared at δ~C~ = 59.4 (d, ^1^ *J* ~P--C~ = 148.6 Hz). A plausible mechanism for the formation of tetrazolopyridazinophosphonate **4** is presented in [Scheme 1](#C1){ref-type="fig"}. Upon heating, the equilibrium between the azido-**1a** and its isomeric tetrazolo-**1b** form \[**1a** ![](Beilstein_J_Org_Chem-09-1730-i001.jpg) **1b\]** lies exclusively at the tetrazole isomer **1b** \[[@R29]\]. Compound **1b** is then intercepted by the nucleophilic attack of the phosphonyl carbanion **2a** or **2b** on the azido-function in **1b** yielding the phosphonate intermediate **3** along with the evolution of a nitrogen molecule. Subsequent intramolecular ring closure, the fused imidazolo-phosphonate **4** would be obtained under elimination of an appropriate alcohol moiety.

![Synthesis of substituted diethyl oxophosphonate **4**.](Beilstein_J_Org_Chem-09-1730-g003){#C1}

In the same fashion, the substrate **1b** reacted with the phosphonyl carbanion, diethyl cyanomethylphosphonate **5**, in ethanolate solution to yield diethyl 8-aminoimidazo\[1,2-*f*\]tetrazolo\[1,5-*b*\]pyridazin-7-ylphosphonate (**7**) in 74% yield. The IR spectrum of the phosphonate **7** (δ~P~ **=** 27.8 ppm) showed the NH~2~, P=O, and P--O--C motifs at ν 3377--3330, 1226, and 1123 cm^−1^, respectively. Its ^1^H NMR (CDCl~3~) spectrum showed the NH~2~-protons at δ 6.44 (H^A^, br) and 8.88 ppm (H^B^, br), which are attributed to the P=O bonding with one proton of the amino-group. Furthermore, the ^13^C NMR spectrum of **7** revealed, among others, three doublets at: δ 153.6 \[d, ^3^ *J* ~P--C~ = 11.4 Hz, C(2)\], 141.2 (d, ^1^ *J* ~P--C~ = 188.4 Hz, C(4)--P), and at δ 126.4 (d, ^2^ *J* ~P--C~ = 14.6 Hz, C(5)*--*NH~2~) ppm. As displayed in [Scheme 2](#C2){ref-type="fig"}, the formation of the fused imidazophosphonate **7** was formed via the initial condensation intermediate **6**. Further alkaline hydrolysis of the cyano group and the intramolecular cyclization led to the product **7** ([Scheme 2](#C2){ref-type="fig"}).

![Synthesis of substituted diethyl aminophosphonate **7**.](Beilstein_J_Org_Chem-09-1730-g004){#C2}

Conversely, similar treatment of **1b** with diethyl (methylthioalkyl)phosphonates **8a** and **8b** under the same reaction conditions yielded the fused diazaphospholo-substituted compounds **10a** and **10b** in 72 and 74% yield, respectively. The ^31^P NMR spectrum (CDCl~3~) of the diazaphospholes **10a** and**10b** showed a sharp singlet around 14.5 ppm, which is within the range expected for the assigned structure \[[@R31]\].

A mechanism for the formation of the heterophosphole structure **10** can be rationalized as in [Scheme 3](#C3){ref-type="fig"} through the condensation of **1b** with **8a** or **8b** to elaborate the intermediates **9a** or **9b** accompanied by the elimination of a N~2~ molecule. Further intramolecular cyclization of **9** afforded the diazaphospholes **10a** and **10b,** respectively, through the loss of an ethanol molecule \[[@R31]\] ([Scheme 3](#C3){ref-type="fig"}).

![Synthesis of fused diazaphospholo-substituted compounds **10a, 10b**.](Beilstein_J_Org_Chem-09-1730-g005){#C3}

Next, the fused imidazophosphono-substituted compound **13** (68% yield) was obtained from the reaction of **1b** with diethyl (2-amino-2-thioxoethyl)phosphonate (**11**) in ethanolate solution. Obviously, **13** resulted in the same manner from the intermediate **12** initially formed, as outlined in [Scheme 4](#C4){ref-type="fig"}.

![Synthesis of fused imidazophosphono-substituted compound **13**.](Beilstein_J_Org_Chem-09-1730-g006){#C4}

Further, the azidotetrazole **1b** was allowed to react with the Horner--Emmons (HE) reactant, tetraethyl methylenebis(phosphonate) (**14**) under the same reaction conditions to give the respective β-enaminobisphosphonate **15** (≈73% yield). The gem-diphosphonate structure **15** was delineated from IR, NMR and MS spectra. The IR absorptions for **15** showed the 2 P=O stretching frequencies as two bands at 1262 (P=O, free) and 1226 (P=O, bonded) cm^−1^, which could be explained by a preferred conformation of intramolecular hydrogen bonding between the NH proton and one of the P=O moieties. The ^31^P NMR spectrum (CDCl~3~) of **15** showed the presence of two separate doublets with equal ^2^ *J* ~P--P~ coupling constants 28.4 Hz at δ 25.6 and 24.8 ppm. The ^1^H and ^13^C NMR data were also in accordance with the assigned structure (see [Supporting Information File 1](#SD1){ref-type="supplementary-material"}). The formation of **15** can be rationalized as occurring in [Scheme 5](#C5){ref-type="fig"} through the addition of **14** to the azido group with concomitant evolution of a molecule of N~2~ ([Scheme 5](#C5){ref-type="fig"}). Bisphosphonates belong to an important class of BP-drugs used for the treatment of bone diseases such as osteoporosis, hypocalcemia, inflammation and rheumatoid arthritis \[[@R32]--[@R33]\].

![Synthesis of β-enaminobisphosphonate **15**.](Beilstein_J_Org_Chem-09-1730-g007){#C5}

Finally, we studied the behavior of the azidotetrazole **1b** toward the unsaturated HE reactant, diethyl vinylphosphonate (**16**), and diethyl 2-methylallylphosphonate (**18**) in EtONa solution to give the fused imidazophosphono-substituted compounds **17** (76%) and **19** (74%). Obviously, according to [Scheme 6](#C6){ref-type="fig"}, the coupling cyclization reaction of **1b** with **16** and auto-oxidation resulted in formation of the final product **17** in one step. This behavior is familiar in similar reactions. On the other hand, we presume that the allyl reagent **18**, which could be present in the isomeric forms **18a** ![](Beilstein_J_Org_Chem-09-1730-i002.jpg) **18b** ([Scheme 7](#C7){ref-type="fig"}), had been conjugated in **18b** form with **1b** to give the phosphonate **19**.

![Synthesis of fused imidazophosphono-substituted compounds **17** and **19**.](Beilstein_J_Org_Chem-09-1730-g008){#C6}

![Isomeric forms of diethyl 2-methylallylphosphonate (**18**).](Beilstein_J_Org_Chem-09-1730-g009){#C7}

In summary, it has been found that the substrate 3,6-diazidopyridazine reacts with nucleophilic phosphorus reagents, HE reactants, mainly in the tetrazole-form leading to the formation of tetrazolopyridazino-imidazophosphor esters or β-enaminophosphor esters.

Biological assays
=================

Based on previous reports \[[@R24]--[@R26]\] that recognized the pyridazine nucleus is being suitable for anti-inflammatory and antinociceptive agents, and by the fact that ring-fused heterocycles containing more than one nitrogen atom (e.g., tetrazole nuclei \[[@R21]--[@R23]\]) are key structures in a large variety of biochemical processes, bioscreening of the synthesized substituted tetrazolo\[1,5-*b*\]pyridazine-phosphor derivatives was carried out. Thus, keeping the tetrazolopyridazine core structure intact, we studied the effect of different phosphorus-containing moieties on their antinociceptive and anti-inflammatory effects. Substrate **1** was also tested to reflect the effect of its transformations to our products.

Antinociceptive evaluation *para*-Benzoquinone (*p*-BQ)-induced writhing test
-----------------------------------------------------------------------------

The evaluation of antinociceptive activity of the synthesized compounds was assessed in vivo in mice by using the *p*-benzoquinone-induced writhing test \[[@R26]\]. Ibuprofen was used as a positive control in our experiments; the antinociceptive capacity was expressed as the percentage change compared to writhing controls. The results shown in [Table 1](#T1){ref-type="table"} indicated that β-enaminobisphosphonate **15** is the most potent antinociceptive structure (86.4%), which was followed by α-aminophosphonates **13** (84%) and **7** (81%). Indeed, while the azido substrate **1** showed only a weak antinociceptive effect (14%), the eight phosphor compounds demonstrated higher capacity than the reference ibuprofen drug (69.9%) at the same dose of 50 mg per kilogram body weight.

###### 

Antinociceptive/anti-inflammatory effects of the tested compounds on the *p-*BQ-induced abdominal constriction test and carrageenan (CG)-induced hind paw edema model in mice.^a^

  -------------- -------------------------------- -------------------------------------------- --------------------------------------------- --------------- -------------- ------------
  tested\        no. of writhings ± SEM\          Swelling in thickness (× 10^−2^ mm) ± SEM\   anti-inflammatory activity after 360 min, %                                  
  compound       (antinociceptive effect, %^b^)   (inhibition of edema, %)^c^                                                                                               

                                                                                                                                                                            

                 90 min                           180 min                                      270 min                                       360 min                        

                                                                                                                                                                            

  control        28.6 ± 2.4                       41.4 ± 3.3                                   55.2 ± 2.7                                    74.8 ± 3.6      78.2 ± 4.1     ---

  **4** ^d^      6.8 ± 2.2\                       30.2 ± 3.8\                                  28.9 ± 4.6\                                   37.4 ± 5.7\     31.3 ± 5.6\    (96.8)\*\*
                 (76.2)\*                         (27.1)\*                                     (47.6)\*\*                                    (50.0)\*\*      (60)\*\*\*     

  **7** ^d^      5.4 ± 4.3\                       31.8 ± 5.3\                                  25.1 ± 5.6\                                   33.8 ± 3.4\     27.4 ± 6.4\    104.8
                 (81.1)\*\*                       (23.2)\*                                     (54.5)\*                                      (54.8)\*\*\*    (65.0)\*       

  **10a** ^d^    5.8 ± 2.9\                       30.6 ± 6.3\                                  26.3 ± 5.6\                                   34.6 ± 3.6\     27.9 ± 4.3\    103.7
                 (79.7)\*\*\*                     (26.1)\*\*                                   (52.4)\*\*                                    (53.7)\*\*\*    (64.3)\*\*\*   

  **10b** ^d^    6.3 ± 2.9\                       30.8 ± 3.8\                                  27.1 ± 4.7\                                   35.6 ± 6.0\     28.8 ± 4.8\    102
                 (77.9)\*                         (25.6)\*                                     (50.9)\*                                      (52.4)\*\*\*    (63.2)\*\*\*   

  **13** ^d^     4.4 ± 2.2\                       30.7 ± 3.3\                                  23.4 ± 5.6\                                   33.2 ± 3.6\     25.8 ± 4.3\    108
                 (84.6)\*                         (25.8)\*\*                                   (57.6)\*\*                                    (55.6)\*\*\*    (67.0)\*\*\*   

  **15** ^d^     3.9 ± 2.1\                       28.9 ± 5.2\                                  21.6 ± 7.4\                                   28.2 ± 5.0\     22.8 ± 6.7\    114
                 (86.4)\*\*                       (30.2)\*\*\*                                 (60.9)\*\*\*                                  (62.3)\*\*\*    (70.8)\*\*\*   

  **17** ^d^     7.6 ± 1.7\                       30.4 ± 7.2\                                  29.3 ± 4.1\                                   39.1 ± 4.2\     30.7 ± 4.5\    97.9
                 (73.4)\*\*\*                     (26.5)\*\*\*                                 (46.9)\*\*                                    (47.7)\*\*\*    (60.7)\*\*\*   

  **19** ^d^     7.2 ± 2.1\                       29.7 ± 4.6\                                  28.7 ± 5.6\                                   38.5 ± 5.2\     31.9 ± 3.8\    95.5
                 (74.8)\*\*\*                     (28.0)\*                                     (48.0)\*\*                                    (48.6)\*\*\*    (59.2)\*\*\*   

  **1**          24.6 ± 2.3\                      36.8 ± 6.9\                                  44.6 ± 5.4\                                   56.8 ± 5.5\     62.4 ± 3.8\    32.6
                 (14.0)\*\*                       (11.1)\*\*                                   (19.2)\*\*                                    (24.0)\*\*      (20.2)\*\*\*   

  ibuprofen      8.7 ± 3.1\                                                                                                                                                 
                 (69.6)\*\*\*                                                                                                                                               

  indomethacin                                    34.6 ± 4.6\                                  32.4 ± 4.4\                                   31.4 ± 1.6\     29.8 ± 3.4\    100
                                                  (16.4)\*\*                                   (41.3)\*                                      (58.02)\*\*\*   (62.0)\*\*\*   
  -------------- -------------------------------- -------------------------------------------- --------------------------------------------- --------------- -------------- ------------

^a^Data obtained from animal experiments are expressed as means ± SEM (dose = 50 mg per kilogram body weight, administered subcutaneously to mice (*n* = 6--8). ^b^ *p*-BQ-induced writhing; ^c^CG-induced paw edema tests, respectively. ^d^Statistical significance was evaluated from the control by one-way ANOVA post hoc Dunnett's test (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001).

Anti-inflammatory screening
---------------------------

### Carrageenan-induced hind paw edema test

Anti-inflammation properties of the new tetrazolo\[1,5-*b*\]pyridazines-bearing mono- (**4**, **7**, **10a**, **10b**, **13**, **17**, **19**) and diphosphonate nuclei (**15**) were evaluated in an animal model, by the carrageenan--induced paw edema (CPE) method. Following the standard procedures \[[@R34]--[@R35]\], these compounds were administered subcutaneously by using 50 mg per kilogram body weight, and the anti-inflammatory effect was measured at successive time intervals (90, 180, 270, and 360 min, after carrageenan injection). The results are profiled in [Table 1](#T1){ref-type="table"} and are compared to the substrate **1** and to indomethacin (**A**). β-Enaminobisphosphonate **15** showed the most potent inflammatory properties (e.g., 114% after 360 min) relative to indomethacin. Nevertheless, other compounds displayed good to excellent effects (95 to 108%) in inflammation inhibition after 360 min comparing to **A** without toxic effects. Percentage inhibition of granuloma for the tested compounds at a dose of 50 mg per kilogram body weight at successive intervals is displayed in [Fig. 1](#F1){ref-type="fig"}.

![Percentage inhibition of granuloma for the tested compounds at a dose of 50 mg per kilogram body weight after the given time intervals. Error bar: 5%.](Beilstein_J_Org_Chem-09-1730-g002){#F1}

According to the results of the biological assay in [Table 1](#T1){ref-type="table"}, we could deduce the structure--activity relationship (SAR) as follows: (1) among the tested compounds, β-enaminobisphosphonate **15** has the most antinociceptive/anti-inflammatory activity, even higher than the references ibuprofen and indomethacin; (2) there is a parallel correlation between the anti-inflammatory activities and the antinociceptive activity results ([Table 1](#T1){ref-type="table"}); (3) the amino group substituent has a positive effect (see **7** and **13**); (4) like indomethacin, the tested phosphonates showed gradual increase in the second phase (after 270 min).

### LD~50~ of the most promising products

In an acute-toxicity experiment, the most promising anti-inflammatory compounds **15**, **7**, and **13** were tested using the LD~50~ standard method in mice at doses of 500, 750 and 1000 mg per kilogram body weight, which is 10--20 times the used anti-inflammatory effective dose (50 mg per kilogram body weight). The assay did not show toxic symptoms or mortality rates throughout the following 24 h post-administration, indicating the safety of the used doses.

Conclusion
==========

In summary, we have offered a practical and efficient procedure for the synthesis of imidazophosphor esters based tetrazolo\[1,5-*b*\]pyridazine in high yields by application of different types of Horner--Emmons (HE) reagents on 3,6-diazidopyridazine. Among the products, the β-enaminobisphosphonate compound demonstrated the highest antinociceptive and the anti-inflammatory activities.

Experimental
============

See [Supporting Information File 1](#SD1){ref-type="supplementary-material"} for full experimental data

Supporting Information
======================

The experimental section, the general procedures, the experimental data, the results of the analyses, and the bioassay procedures are included in [Supporting Information File 1](#SD1){ref-type="supplementary-material"}.
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Full experimental details.
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